A new blood test for the early detection of Alzheimer's

A new blood test for the early detection of Alzheimer's

The American television channel Fox News reported last night (Wednesday) on a groundbreaking approach to the fight against Alzheimer's and dementia, emphasizing the critical role of early diagnosis and proactive intervention. The innovative approach in Melissa Rudy's article dealt with the real potential of delaying and slowing the progression of Alzheimer's.

The article also noted that the deaths recorded as a result of Alzheimer's disease in the United States jumped 141% from 2000 to 2021, and today approximately 6.9 million Americans are living with the disease, according to a new report by the Alzheimer's Association. One of the most striking aspects of this new approach is the emphasis on early detection.

Because the progress of scientific knowledge, in the ability to diagnose and through laboratory tests now allow earlier and more accurate diagnosis of the disease. The early detection significantly increases the chance of benefiting from old drugs to reduce the symptoms, from new drugs to clear the amyloid protein and joining clinical trials of future treatments.

In connection with this, Prof. David Tana, an expert in neurology, director of the Institute for Stroke and Cognition at Rambam, states that: “Early and accurate diagnosis of Alzheimer's disease can help in the process of examining suitability for receiving drug treatment that can slow down the course of the disease, only if it is given in an initial stage where it is I may still be effective.'

“At the same time, such an early diagnosis can also encourage a fundamental change in lifestyle in order to delay the progression of the disease.” Prof. Tana, the outgoing chairman of the Neurological Association, who serves as a consultant for a new blood test in Israel to diagnose Alzheimer's called AD-Detect even explained that: “Neurologists in Israel “Alzheimer's disease can be diagnosed accurately and at an early stage in the world using innovative biological markers and not only with old clinical methods that we have used until today,” he added.

“The accurate early diagnosis is the beginning of a revolution in the field and provides the possibility of pharmaceutical intervention and lifestyle changes to slow down and delay the disease processes,” he said in conclusion.

It should be noted that in Israel, according to the estimate of the Amda association, about 150,000 women and men are currently dealing with dementia and Alzheimer's. According to the Ministry of Health's forecast, by the year 2050, the number of patients in Israel will triple.

The new blood test called AD-Detect and designed for the early diagnosis of Alzheimer's with a high level of accuracy using biological markers (biomarkers) is exclusively represented in Israel by the Medical Link company and is designed to detect a high concentration of amyloid beta protein which indicates Alzheimer's. The test was developed by the American diagnostics giant Quest Diagnostics, which even deciphers the blood samples that are sent from Israel on a flight to a laboratory in California.

The test is already available throughout the country and is intended for women and men of any age who have a referral from a doctor who, as part of the medical investigation of their cognitive status, were referred for further testing. The test is included in most private health insurances and the Medical Link company estimates that the supplementary insurances of the health funds are also expected to join soon. To make an appointment, call the Medical Link hotline staffed 24/7 at *5901 or go to the website at the following address: click here

Illustration. Photo: Pexels

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Enable Notifications OK No thanks